SPY314.38-1.80 -0.57%
DIA257.24-3.48 -1.33%
IXIC10,547.75+55.25 0.53%

Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $100

Needham analyst Alan Carr maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $150 to $100.

Benzinga · -
Needham analyst Alan Carr maintains Intercept Pharmaceuticals (NASDAQ: ICPT) with a Buy and lowers the price target from $150 to $100.